neuroClues’ Post

Breaking Ground in #Alzheimers Research: Recent studies indicate that blood tests for Alzheimer's hallmarks - beta amyloid and phosphorylated tau - can detect brain pathology years before cognitive decline. Blood-based tests offer low-cost, non-invasive diagnostic tools to support early disease intervention. The FNIH Plasma Abeta/pTau Project (https://bit.ly/42g6csp) is leading the way, using data to identify early signs of Alzheimer's Disease (AD) through a simple blood test. Leveraging Alzheimer's Disease Neuroimaging Initiative (ADNI) investments, this team is compiling the largest longitudinal, cross-platform AD hashtag#biomarker dataset to date, fostering trust in these tests through precompetitive collaborative efforts. Join us in the quest for next-gen markers to understand the diverse drivers of Alzheimer's. Interested? Let us know! https://lnkd.in/gXka4Rfx Blood-based AD tests in the news: NPR: https://lnkd.in/eGaUZgDJ   CNN Health: https://lnkd.in/eh2Knmsa TIME: https://lnkd.in/edviXKwQ #AlzheimersResearch #BrainHealth #EarlyDetection #MedicalResearch #FNIHProject #Biomarker #ADNI #Neuroscience #HealthScience #CognitiveHealth #HealthcareInnovation #ResearchCollaboration #tau #Alzheimers #BloodTest  #BetaAmyoid #FNIH #BiomarkersConsortium

Brain Awareness Week continues and this time it brings with it the topic of stroke. Stroke is one of the leading causes of disability, dementia, epilepsy, or death. The number of people affected by stroke is increasing due to the aging of the population, and therefore new diagnostic and therapeutic strategies are needed. Cooperation between the academic and business spheres can help to achieve necessary results. BioVendor Group is part of the STROKE BRNO research cluster. The mission is the interdisciplinary linking of the research institutions and university hospital with the involvement of experienced experts and talented young scientists and cooperation with the government. We also cooperated on the development of new methods in the diagnostics of stroke as a part of the INBIO project, which ended in 2023. One of the goals of the project was the development of thrombolytics for the treatment of stroke. Thrombolytics are also a strong research topic at Loschmidt Laboratories, Faculty of Science, Masaryk University and RECETOX. We are very proud to be part of the stroke scientific community, helping stroke patients by building up an efficient scientific network to accelerate the development of innovative treatments. INBIO, Engineering of New Biomaterials and Biopharmaceuticals for the Diagnosis and Treatment of the Cerebrovascular and Neurodegenerative Diseases, CZ.02.1.01/0.0/0.0/16_026/0008451 #BioVendorGroup #brainweek #brainweek2024 #brain #neuroscience #alzheimer #alzheimersdisease

The integration of #Alzheimer's blood tests into clinical care will represent a significant advancement in accurate and minimally-invasive screening. As momentum builds, the identification of new treatment targets and #biomarkers becomes crucial. Initiatives like Accelerating  Medicines Partnership® (AMP®) Alzheimer's Disease play a pivotal role in advancing target and biomarker discovery for Alzheimer's Disease (AD). AMP AD's commitment to driving precision medicine research positions it as a crucial ally in unraveling the intricacies of Alzheimer's. These efforts guide us toward a future where targeted treatments offer relief to patients grappling with this disease. https://lnkd.in/eUbhiPbq AMP AD and more will be discussed at the upcoming AMP Symposium! https://lnkd.in/eFN93ZWt #AlzheimersResearch #BrainHealth #EarlyDetection #MedicalResearch #FNIHProject #Biomarkers #AMP #FNIH #Neuroscience #HealthScience #CognitiveHealth #HealthcareInnovation #ResearchCollaboration #Alzheimers #BloodTest 

Predicting Dementia with Advanced Brain Scans 🔍 Early Detection Breakthrough: New brain scanning technology can predict dementia up to 9 years before symptoms appear. 🧠 Innovative Imaging Techniques: The study used imaging techniques to identify early biomarkers of dementia, improving early diagnosis. 📈 Potential for Early Intervention: Early detection could allow for timely interventions and better management of the disease, potentially delaying onset. #Dementia #BrainScans #EarlyDetection #Neuroscience #MedicalResearch If there are simpler means to capture brain changes, i.e. blood biomarkers without having to resort to expensive equipment, would be the way forward. Its a good start and further work with individuals to screen out other indicators is the way forward. Read more: https://lnkd.in/eRyDGyHa Full article: https://lnkd.in/ebZ8QRqU

It seems exciting developments in the Alzheimer’s space keep coming: yesterday the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced a transformative shift in Alzheimer’s diagnostics—blood tests are now pinpointing amyloid plaques with the precision needed for clinical use. This leap forward means less invasive, more accessible testing for patients, and by opening the study’s detailed datasets, we can accelerate the pace of innovation, pushing us closer to new solutions in Alzheimer’s care. Looking ahead, I’m excited to join the FNIH’s Team Science Day on September 16 in New York. We're bringing together the best from the public and private sectors tackling health's toughest challenges. Expect insights from top minds like The National Institutes of Health's Monica Bertagnolli and FDA’s Peter Marks. Learn more here: https://lnkd.in/gPSVSJs8 Together, we’re making waves in healthcare innovation – let’s keep pushing the boundaries! #Innovation #Alzheimers #PowerofPublicPrivatePartnership #HealthcareLeadership #ScienceRules

Meet Assistant Professor Anna M. Barron, our newly appointed EMBO Global Investigator. 🌐 Her groundbreaking research delves into the intricate role of mitochondria in brain development, health, and neurodegenerative disorders like Alzheimer's. By putting mitochondria on the map, her work unravels the mysteries of how these energy powerhouses influence diverse brain cell types, from neurons to microglia. 💡 🔬🌍 Despite the challenges posed by the pandemic, Anna's dedication to advancing knowledge in the field remains unwavering. As an EMBO Global Investigator, she looks forward to the collaborative opportunities that will broaden the impact of her research on an international scale. 🤝 Learn about Asst Prof Anna Barron and her research on cellular metabolism as a regulator of microglial fate and function: https://lnkd.in/gcdZA6g9 Read the Announcement: https://lnkd.in/gpVJipEP #EMBO #ScienceCommunity #Neuroscience #ScientificBreakthroughs #ResearchExcellence #Research #MedicalInnovation #LKCMedicine

At PurMinds NeuroPharma, we are dedicated to developing groundbreaking therapies for neurodegenerative diseases. These conditions affect millions of individuals and their families, posing significant challenges to healthcare systems worldwide. Consider these statistics: Mild Cognitive Impairment: Impacting >12 million people in the U.S. and expected to rise to >20 million by 2060. MCI patients are at a greater risk of developing Alzheimer’s disease or a related dementia. Alzheimer’s Disease: Affects over 6 million people in the U.S. alone, with numbers expected to rise to 13 million by 2050. Parkinson’s Disease: Over 10 million people worldwide live with this condition. ALS: Approximately 30,000 people in the U.S. are living with ALS at any given time. Our approach focuses on creating novel, effective treatments that address the root causes of neurodegenerative disease, with our lead program focussing on MCI as its first clinical indication. Learn more about our work at purminds.com #NeurodegenerativeDiseases #InnovativeTherapies #Neuroscience #HealthcareInnovation #PatientCare

Today at #AAIC24, a study by the FNIH Biomarkers Consortium will be presented comparing the accuracy of leading blood tests in detecting amyloid plaques, a characteristic of Alzheimer’s disease. The results demonstrate that some blood tests are accurate enough for clinical use and could replace spinal taps and brain scans for diagnosing patients with cognitive impairment. The latest advances in blood tests mark a significant step forward in Alzheimer's research, addressing a critical need for more accessible and less invasive diagnostic tools. The rich dataset generated by this collaborative study is freely available to the scientific community to use for further research, accelerating the development of Alzheimer’s diagnostic tools and therapeutic options. To read the preprint article, click here: https://lnkd.in/eAec25FC Read the full announcement here: https://lnkd.in/eY88j9-Z #Alzheimer #AlzheimersResearch #FNIH #BridgestoBreakthroughs #BiomarkersConsortium #AmyloidPlaques #BloodTests #EarlyDiagnosis #Neuroscience

📖 A recent study explores the engram, a concept that refers to the physical manifestation of memory in the brain, and its implications for dementia and Alzheimer’s disease. Focusing on hippocampal neurogenesis, this research offers insights into memory circuit disruptions in dementia and employs advanced techniques for the precise manipulation of engram cells. 💡 Highlights: 1. The engram, a key to understanding memory storage and retrieval, shows how hippocampal neurogenesis impacts both healthy and Alzheimer's-affected brains. 2. Advanced opto- and chemogenetics facilitate precise manipulation of engram cells, allowing for a deeper understanding of memory processes. 3. The integration of mature and immature neurons in the dentate gyrus's engram offers fresh perspectives on memory formation and Alzheimer’s disease. 4. Memory engram research points towards novel therapeutic strategies for dementia, emphasizing the role of neurogenesis and neuron integration. Insights into memory reconsolidation reveal how memories are modified upon retrieval, suggesting potential for retrieving lost memories in Alzheimer's disease. Check out for more: https://lnkd.in/dYWmYne3 #Neuroscience #AlzheimersResearch #MemoryCircuits #Engram #HippocampalNeurogenesis #BrainHealth

November is #epilepsyawarenessmonth. Epilepsy is one of the most common neurological disorders, affecting more than 45,000 people of all ages in Ireland today. Dr Cristina R Reschke is a funded investigator in FutureNeuro, the Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases which is hosted at the Royal College of Surgeons in Ireland (RCSI). Currently, the overarching theme of Cristina’s research is to understand the interplay between circadian rhythm regulation and epilepsy, exploring the molecular and genetic mechanisms involved, and on the pre-clinical discovery of novel treatments for the prevention of seizures through brain-targeted drug delivery. Discover more about Cristina's research, and other FutureNeuro research themes and PIs by visiting https://lnkd.in/d7eehGxN FutureNeuro connects SME and multinational industry partners with leading Irish scientists in neurological investigation and a research-active clinical network to design and deliver patient-centered translational research. If you would like to learn more about opportunities for your company to engage with the Centre, please reach out for an informal discussion. #neuroscience #epilepsy #collaborativeresearch